New heart scan could speed up amyloidosis diagnosis

NCT ID NCT07605741

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will test whether a faster type of bone scan (CZT-SPECT) can accurately diagnose transthyretin cardiac amyloidosis, a serious heart condition. Researchers will compare the new scan with the standard method in 200 patients. If it works, it could make diagnosis quicker and easier.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

bone scintigraphy (CZT-SPECT and conventional camera)

What this could lead to

If successful, this could make diagnosing cardiac amyloidosis faster and more reliable, potentially improving patient care.

What could go wrong

This is an early-stage diagnostic study, not a treatment trial. The new scan may not match the accuracy of current methods, and results may not apply to all patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIAC AMYLOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Amyloid Neuropathies, Familial amyloidosis wild type ATTR amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••